Eli Lilly and Company (NYSE:LLY) Trading 4.9% Higher After Better-Than-Expected Earnings

Shares of Eli Lilly and Company (NYSE:LLY) were up 4.9% on Wednesday following a stronger than expected earnings report. The stock traded as high as $1,216.94 and last traded at $1,170.2960. Approximately 6,403,230 shares were traded during trading, an increase of 104% from the average daily volume of 3,135,686 shares. The stock had previously closed at $1,115.68.

The company reported $8.38 EPS for the quarter, beating the consensus estimate of $6.06 by $2.32. The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.69 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s revenue was up 47.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Blowout second-quarter results: Lilly reported non-GAAP earnings of $8.38 per share, well above the roughly $6.06 analyst consensus, while revenue rose 47.7% year over year to $22.97 billion versus expectations of about $20.69 billion. Lilly second-quarter earnings report
• Positive Sentiment: GLP-1 demand is driving growth: Strong volume for diabetes drug Mounjaro and obesity treatment Zepbound fueled the revenue and profit beat, with newer pipeline products adding to Lilly’s long-term growth outlook. Lilly earnings and outlook article
• Positive Sentiment: Full-year outlook raised: Lilly now expects 2026 revenue of $85 billion to $87 billion, up from its previous $82 billion to $85 billion forecast. It also issued EPS guidance of $35.50 to $36.50, supporting estimates of continued earnings momentum. Reuters Lilly revenue forecast article
• Positive Sentiment: Additional commercial and pipeline catalysts: CVS Health is expanding its weight-management program through a Lilly partnership, while Lilly is providing limited early access to experimental obesity drug retatrutide and advancing cancer drug olomorasib. These developments strengthen Lilly’s distribution and future-product narratives. Lilly financial results and pipeline update
• Negative Sentiment: Capacity and valuation remain risks: Executives acknowledged that manufacturing and supply capacity could limit how quickly Lilly converts virtually unlimited GLP-1 demand into sales. At roughly a $1.1 trillion market capitalization and a forward-looking valuation near 41 times earnings, the stock also has limited room for execution disappointments.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Wall Street Zen lowered Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Guggenheim raised their price objective on Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the stock a “buy” rating in a research note on Monday, July 13th. The Goldman Sachs Group reiterated a “buy” rating and issued a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. UBS Group boosted their price target on Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Leerink Partners boosted their price objective on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday, June 25th. Two research analysts have rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $1,283.64.

Institutional Investors Weigh In On Eli Lilly and Company

Hedge funds have recently modified their holdings of the business. Maryland Capital Advisors Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth approximately $25,000. Osbon Capital Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at $25,000. Basso Capital Management L.P. acquired a new position in Eli Lilly and Company in the fourth quarter valued at about $30,000. E Fund Management Hong Kong Co. Ltd. lifted its holdings in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock worth $32,000 after acquiring an additional 24 shares during the last quarter. Finally, New England Capital Financial Advisors LLC boosted its position in shares of Eli Lilly and Company by 142.9% during the fourth quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock worth $37,000 after buying an additional 20 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 4.9%

The business has a fifty day moving average of $1,154.75 and a 200 day moving average of $1,044.52. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a market capitalization of $1.10 trillion, a PE ratio of 41.57, a PEG ratio of 1.39 and a beta of 0.51.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.